Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — How Brands in the Marijuana Market Can Drive Innovation

In the recent past, we have seen the rapid increase in personal wellness products and growing public health concerns create more proactive and health-conscious consumers. New market research shows that 70% of consumers purchase certain food products that have functional benefits to support their physical and mental well-being.

As more individuals begin prioritizing their health, the marijuana industry is afforded the opportunity to develop formulations that cater to these varied and evolving consumer preferences. Brands involved in the space can now create products that showcase the plant’s numerous applications by harnessing the power of minor cannabinoids and less popular terpenes instead of remaining focused on how they can continue developing more CBD and THC products.

Below are some ways players in the industry can drive innovation within the space and allow for more scientific studies on the plant’s benefits to be conducted.

Creating products to help with sleeping issues

At the moment, millennials make up the biggest share of marijuana consumers in America. This group often struggles with sleep disorders and experiences high levels of stress, which explains why they use sleep aids more than their gen X and baby boomer counterparts.

When developing new products, players in the industry may benefit from paying close attention to this type of information as well as other lifestyle habits of this group. Brands may formulate products that have been designed to optimize sleep. For instance, CBG and CBN can be paired with terpenes such as linalool and nerolidol to help consumers rest.

Creating products that allow for healthy decompressing

After a long day, many individuals like to unwind and relax. Infusion technology can be used to create cannabis drinks that are not only healthy but also afford their consumers euphoric and relaxing experiences.

Brands may use terpenes such as limonene and myrcene to create such experiences through their products, which will help drive consumption and address growing consumer demand.

Creating products that enhance an individual’s performance

Consumers in the market also seek products that enhance their physical and mental performance, which can explain the increasing demand for energy drinks. Recent research has found that minor cannabinoids such as THCv can enhance energy metabolism while terpenes such as pinene, limonene and beta-caryophyllene can improve focus. This is in addition to improving cognitive function and increasing energy.

Focusing on the creation of beverages with such compounds may benefit both companies and consumers, especially as more consumers consume less sugar-sweetened drinks.

Companies in this space, such as Prime Harvest Inc., can choose from a variety of different aspects upon which to focus their innovative efforts, and the combination of the different licensed companies working to push the envelope may result in an advanced marijuana industry in the long run.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products… Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product form, including topical, hair care, lip care, and cosmetics,” a recent article reads. “Lexaria stands to gain substantial revenue through the licensing of DehydraTECH technology across minimum quarterly payments for use by Premier and royalties for products sold… To retain ongoing exclusivity, the minimum quarterly payments from Premier to Lexaria will begin Sept. 1, 2022, and will total US$4,527,500 during the first five years of the agreement. Additional payment beyond five years will be required to keep the license in good standing.”

To view the full article, visit https://cnw.fm/SKDNR

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 26 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Helps Farmers Expand into Highly Profitable Markets, Maintain Year-Round Revenue Streams

Advanced Container Technologies (OTC: ACTX) today announced that GrowPods, modular hydroponic farms that can be placed virtually anywhere, can help farmers expand into new markets and grow profitable fruits and vegetables year-round. GrowPods have the production capacity equivalent of one acre of traditional farmland in an automated, controlled, pesticide-free environment. According to Entrepreneur 360, farmers are not currently growing the most profitable crops. Adding a GrowPod or two allows farmers to add high-margin specialty crops to their revenue stream. “The GrowPod system allows farmers to move into new, highly profitable markets, and maintain revenue streams year-round,” said Douglas Heldoorn, CEO of Advanced Container Technologies. “With GrowPods, farming can be done in a controlled environment allowing farmers to eliminate pesticides and contaminants, yielding a highly desirable crop that is even better than organic.”

To view the full press release, visit https://cnw.fm/e8CcQ

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Sugarmade Inc. (SGMD) Subsidiary Inks MSA for Manufacturing, Distribution Expansion

Sugarmade (OTC: SGMD) subsidiary SugarRush has signed a management services agreement (“MSA”) with Canndis Inc., a California cannabis micro-license holder. The MSA outlines an expansion for the company’s manufacturing and distribution operations based on Canndis’ license, which includes delivery, manufacturing, distribution and cultivation capabilities. The MSA calls for Sugarmade to take over cannabis product manufacturing, distribution, delivery licensing and facility management ahead of Canndis’s first harvest at its Jerusalem Grade Farm; the farm is licensed for 43,560 square feet of outdoor canopy area and is growing at full capacity this season. According to the announcement, the MSA provides for the establishment of a new strategically located manufacturing and distribution hub. Sugarmade is an emerging leader in the licensed cannabis sector. “This deal will provide us with a new income stream as we apply our expertise and experience to mobilize Canndis’ assets and market positioning,” said Sugarmade CEO Jimmy Chan in the press release. “But it also has substantial strategic value because it lays a foundation for a significantly expanded manufacturing and distribution infrastructure under our control when we harvest our first crop in two months.”

To view the full press release, visit https://cnw.fm/wg9jD

About Sugarmade Inc.

Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush(TM), NUG Avenue, J Grade Farm, Lemon Glow and Budcars. For more information about the company, please visit www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://cnw.fm/SUGAR

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CWN — Four Recent Medical Marijuana Studies Worth Knowing About

A significant amount of research has been conducted in the medical marijuana field these last few years, revealing much about how the drug can be used in the management of various conditions. Below is an outline of some new studies on the use of cannabis and cannabis compounds, such as CBD, in the treatment of various conditions, including multiple sclerosis, coronavirus and fibromyalgia.

Use of CBD as potential coronavirus treatment

Figures from the World Health Organization (WHO) show that the coronavirus has caused more than 6.4 million deaths and over the last two years.

A recently conducted literature review assessed studies that tested the use of CBD to manage inflammation caused by the coronavirus. Preclinical medical marijuana studies showed promise for the compound’s impact on inflammatory outcomes of the cornea, gastrointestinal tract and lungs.

However, the authors stated in their conclusion that there wasn’t enough evidence to refute or support CBD as a repurpose medication for the treatment of inflammation and other coronavirus symptoms. They added that more clinical trials were needed to test CBD’s effectiveness.

Use of medical marijuana in managing fibromyalgia pain

Researchers from McGill University, Rutgers, Canopy Growth Corp. and the University of Montreal have assessed the potential mechanisms underlying a decrease in pain among patients with fibromyalgia who use medical marijuana.

The scientists stated that their analyses demonstrated that a decrease in levels of pain in patients could partly be explained by synchronous reductions in negative affect and sleep problems.

In their conclusion, the researchers stated that their findings showed decreases in pain, but this couldn’t be generalized to all patients with fibromyalgia who were using medical marijuana.

Impact of CBD on nerve cells in the brain

Researchers from the University of Milan collaborated with Curaleaf and Imperial College London’s Mikael Sodergren to assess CBD’s potential in treating neurodegenerative and psychiatric disorders.

The researchers focused on the brain-derived neurotrophic factor (BDNF) gene, finding that CBD could regulate the expression of this gene. Low levels of this gene, which promotes nerve cell maturation and growth, have been linked to epilepsy, Alzheimer’s, depression and schizophrenia.

Promising findings for CBD in treating multiple sclerosis

Multiple sclerosis is a chronic neurodegenerative and inflammatory illness of the central nervous system. Common symptoms of this disease include cognitive, motor, sensory and affective disturbances. New data shows that more and more patients with this illness are beginning to use cannabis-based medicinal products to manage their symptoms.

The researchers who conducted the study argue that there are promising indications for the use of cannabis-based medicinal products in the symptomatic treatment of multiple sclerosis.

It is worth noting that many people buy and use products from licensed companies such as Flora Growth Corp. (NASDAQ: FLGC) to obtain relief from a variety of disease symptoms, so it would be beneficial if researchers also studied and provided definitive guidance on the other conditions for which people say they use cannabis.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Suggests Cannabis Users Are Less Likely to Suffer Severe COVID-19 Infections

As the coronavirus pandemic raged on, infecting millions of people across the world and taking thousands of lives each day, there were claims that cannabis use could potentially reduce the risk of contracting the virus. Looking to ascertain whether these claims were factual, researchers began looking at the relationship between cannabis and COVID-19 and found that the controversial drug could indeed reduce the risk of developing coronavirus health complications.

Researchers have now found a link between marijuana consumption and reduced coronavirus severity among patients who were hospitalized due to COVID-19 complications. They say that cannabis could potentially lower the severity of the virus and result in better health outcomes. This is despite the fact that cannabis users involved in the study were five times more likely to use tobacco compared to nonusers.

The study, which involved 1,831 hospitalized patients who had COVID-19, found that cannabis users who were admitted with the coronavirus had a reduced need for mechanical ventilation and ICU admission. It was published in the “Journal of Cannabis Research.” In the report, 4% (69) of the study participants reported using cannabis regularly, with the active cannabis users being younger, less often diabetic, and having higher tobacco smoking rates.

Researchers also found that active cannabis users had fewer inflammatory markers when they were admitted compared to COVID-19 patients who did not use cannabis. They had lower levels of C-reactive protein (CRP), ferritin, D-dimer and procalcitonin compared to nonusers. Furthermore, cannabis users had better health outcomes after infection compared to nonusers, ultimately exhibiting a reduced need for mechanical ventilation (6% vs. 17% in nonusers), lower ICU admission rates (12% vs. 31%) and shorter hospitalization intervals (four days vs. six days).

Study authors believe the better health outcomes associated with regular cannabis use for COVID-19 patients could be due to the medical properties of cannabinoids. Produced by cannabis plants, cannabinoids have been found to have a variety of medical benefits because of their potent anti-inflammatory, antioxidant and antimicrobial properties.

The study said that intubation rates were 6 percentage points lower and ICU admission was 12 percentage points lower in active cannabis users. The researchers concluded that based on their study, it seemed that cannabis users who were admitted with COVID-19 had better clinical outcomes compared to nonusers.

However, the researchers acknowledged that their study had plenty of limitations because it was a retrospective analysis and encouraged interested parties to interpret the results with caution. They called for future observational and prospective studies to get a better idea of how cannabis use can affect COVID-19 patients.

More research is needed to clarify which conditions marijuana may help with so that consumers can be certain that, as they consume the products made by entities such as American Cannabis Partners either recreationally or medically, they can expect to enjoy a given set of benefits based on the compounds present in the specific product they are consuming.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – IBN, CannabisNewsWire to Shine the Spotlight on Cannabis Conference 2022

CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of the 50+ brands within IBN (“InvestorBrandNetwork”), today announced its reengagement by GIE Media to serve as a media sponsor for Cannabis Conference 2022. The unique event, presented by Cannabis Business Times, is slated to take place at the Paris Las Vegas Hotel & Casino in Las Vegas, Nevada, from Aug. 23-25, 2022. Industry participants from more than 30 countries will attend the globally acclaimed conference, which is dedicated to professionals of plant-touching businesses across the cannabis and hemp space. IBN and CannabisNewsWire will leverage their array of extensive corporate communications solutions to heighten recognition for conference participants seeking to enhance visibility among investors, journalists, consumers and the broader public. “GIE Media is a highly professional organization with a wonderful team. The Cannabis Conference is a one-of-a-kind event, and we are very pleased to continue our collaboration with GIE as an official media sponsor,” said Cami Cox, director of analytics and reporting for CannabisNewsWire. “This conference is a stand-out event that provides top-class educational opportunities to industry participants, facilitates networking and showcases the very best in technical advancements.”

To view the full press release, visit https://cnw.fm/gP9LH

About CannabisNewsWire (“CNW”)

CannabisNewsWire, one of 50+ brands within the InvestorBrandNetwork (“IBN”), is a specialized information service that (1) aggregates cannabis news; (2) provides CannabisNewsBreaks to quickly update investors in the space; (3) enhances corporate press releases; (4) provides social media distribution via IBN to millions of social media followers; and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of 5,000+ key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information, please visit www.CannabisNewsWire.com.

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

NECANN 3rd Annual New Jersey Cannabis Convention Brings the East Coast Cannabis Community under One Roof

The NECANN Conference has evolved into the largest conference on the East Coast, attracting cannabis cultivators, traders, regulators, lawmakers, and enthusiasts, from the East Coast and beyond. The 3rd annual New Jersey Cannabis Convention is being held from September 9-10, 2022, in Atlantic City, New Jersey.

This is a well-curated event organized by a highly talented team of professionals with desired expertise and experience. They keep in mind the needs and requirements of the cannabis community and bring together investors, young and veteran cannabis and hemp traders, as well as researchers and lawmakers, all in a common forum.

After fighting a tough battle for legalizing both medicinal and recreational cannabis, New Jersey, on February 22nd, 2021, became the fourteenth U.S. state to legalize marijuana completely. Atlantic City has a huge cannabis market waiting to get discovered and tapped by marijuana traders and customers. Also, the city has very limited cannabis dispensary availability to cater to the entire population. The NECANN exhibition will bring the New Jersey cannabis community to the forefront to get discovered by potential investors.

The 3rd annual NJ NECANN event will witness an important lineup of speakers and industry veterans. They will share useful insights about the latest industry trends and discuss important issues covering the entire range of topics under the cannabis spectrum. Exhibitors can set up their respective booths to pitch their businesses. The 3rd Annual NJ Cannabis Convention will be a one-of-its-kind experience, to discover more cannabis communities and exchange ideas and information about marijuana businesses.

The NECANN team brings in cannabis trade investors and entrepreneurs who are interested in novel and fresh business ideas. Budding entities can leverage the reach of the NECANN platform to gain visibility among potential investors. Established in 2014, NECANN events are one of the largest cannabis conventions offering mammoth networking opportunities. The NECANN events attract Hemp, MMJ, and Cannabis industry professionals, to meet and build critical long-term business ties.

The NECANN convention offers a robust platform for local cannabis businesses to showcase their products and services. It allows them to meet the stalwarts of the cannabis community and attract lucrative investments into the developing New Jersey cannabis market. Overall, the event represents a unique opportunity to get in on the ground floor.

The NECANN team works tirelessly to cover every aspect of the cannabis industry ranging from inventory, legal issues, packaging, insurance, regulations, security, from testing to cultivation, marketing, and more.

To learn more, please visit https://cnw.fm/uJif3

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application

Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA
Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA
Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway
As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if the FDA had required modifications in Lexaria’s current IND-enabling work plan, and Its management is confident that maintaining the current trajectory could allow the company to achieve $1 billion per year in the hypertension market, even making it one of the most effective registered pharmaceutical treatments for hypertension in the world

In the first week of September 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most recent results, at the time, from its HYPER-H21-2 human clinical study on the overall effectiveness of its patented DehydraTECH(TM)-processed CBD on blood pressure. The successful study would play an integral role in the company’s eventual New Drug Application (“NDA”), with Chris Bunka, the company’s Chief Executive Officer (“CEO”), terming the results as “statistically significant” (https://cnw.fm/X9wKM).

The success of multiple human studies investigating DehydraTECH-CBD for hypertension prompted Lexaria to formally announce the process of an Investigational New Drug (“IND”) application filing with the United States Food and Drug Administration (“FDA”) to list DehydraTECH-CBD as a prospective registered pharmaceutical treatment for hypertension.

Lexaria has since received a positive full written response from the FDA regarding DehydraTECH-CBD, with the institution confirming that it agreed to Lexaria’s proposal to pursue a 505(b)(2) NDA regulatory pathway that would hasten the process of commercial approval for its product (https://cnw.fm/Ledb3).

“We are very pleased to have received comments from the FDA toward opening our IND program, and we will be executing FDA-confirmed IND-enabling work immediately,” noted John Docherty, the President of Lexaria.

“We were delighted that our proposals were very well received by the FDA, and the feedback received will be very helpful in compiling and filing our IND application as the new major regulatory step we are focused on moving forward,” he added.

The FDA’s communication also noted that additional non-clinical studies would not be required before initiating the DehydraTECH-CBD IND program, particularly given compelling data already presented by the company and others regarding the safety and tolerability of CBD.

Lexaria is confident that the approval will go through, especially since the FDA already has a history of approving CBD pharmaceutical treatments. In 2018, this approving body gave the green light to Epidiolex(R), a CBD-based pediatric anti-seizure medication. In the approval, they noted that the approved dosage rate for a child weighing 28kg was 140mg, increasing to 280mg daily for long-term use. Lexaria looks to build on this to push for its DehydraTECH-CBD, hoping to offer a viable solution to millions of people living with hypertension.

With the FDA response, Lexaria expects to remain on track to file its complete IND application by late 2022 or early 2023, maintaining the initial targets announced. In addition, given its move to go with the 505(b)(2) pathway as opposed to 505(b)(1), the company looks to shave 6-9 months off of the approval process, bringing its product to the market a lot sooner.

When discussing previous results from the hypertension study, Mr. Bunka noted:

“If we sustain these results, we could be looking at mega-drug status ($1 billion per year) in the hypertension market.”

“Our goal now is to put together a 4-week study, three doses per day, targeting a sustained drop in blood pressure. That could make us one of the most effective registered pharmaceutical treatments for hypertension in the world, with few if any unwanted side effects,” he added.

This outlook shows Lexaria’s commitment to creating shareholder value, even as it inches closer to offering a viable solution to people living with hypertension. In addition, its commitment to following due process to receive FDA approval reflects the company’s and management’s clear vision and understanding of what it would take to grow the list of product offerings and offer something unique in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Influential Nonprofit Says Federal Cannabis Bill Insufficient to Fix Harms of Drug War

The war on drugs was ostensibly started to mitigate drug addiction rates in the country and deal a blow to the criminal enterprises behind the illicit drug trade. However, most experts agree that the decades-long drug war was a failure, leading to the arrest and incarceration of tens of thousands of people on minor drug charges. Furthermore, the drug war exacerbated racial and economic inequality in the country and caused nigh-irreparable damage to marginalized communities.

As cannabis reform has swept across America, most activists and lawmakers have championed cannabis legalization measures that contain social equity provisions designed to repair the harms caused by the drug war. This includes funding various community programs and giving people from marginalized communities a leg-up in the cannabis industry. Senate Majority Leader Chuck Schumer, an avid supporter of cannabis reform, recently introduced a federal marijuana legalization bill that also contains social equity provisions.

However, a major racial justice nonprofit believes that the federal cannabis bill is not sufficient enough to even begin alleviating the racial harms caused by the decades-long prohibition. After reviewing cannabis laws in the United States, the NAACP Legal Defense and Education Fund (LDF) said that waiting for congress to pass cannabis reform would do little to address the racist consequences of the drug war and urged voters in states with cannabis legalization in the fall ballot to come out and vote in favor of legalization.

Schumer kept the country waiting for months as he delayed unveiling his Cannabis Administration and Opportunity Act (CAOA) several times. But now that the legislation has been filed, advancing past both houses of Congress and being signed into law will be a challenge. Additionally, the federal legalization bill won’t be able to help people with cannabis offenses on their records since most of these convictions occurred at the state level.

Simeon Spencer, the operations associate for NAACP LDF’s Thurgood Marshall Institute says that decriminalization as well as expungement on the federal level will offer little benefit to people whose convictions were made under state marijuana regulations. Titled “Redressing America’s Racist Cannabis Laws,” Spencer’s review notes that cannabis criminalization was based on racism and xenophobia, stating that officials outlawed cannabis decades ago to keep Mexican immigrants and Black cultural movements in check.

Media propaganda about Mexican immigrants smoking marijuana was a major contributor to states individually banning cannabis in the following years. According to the NAACP LDF, plenty of Black Americans are currently serving life sentences for cannabis offenses even though the drug is now a multibillion dollar industry. Spencer writes that both the federal governments and state governments will have to work together to adequately mitigate the systemic racial inequalities in cannabis policy.

As those prohibitionist policies are rolled back, a chance could be created for companies such as Advanced Container Technologies Inc. (OTC: ACTX) to serve more people with their innovative products such as the micro gardens transforming the way marijuana and other crops are grown indoors.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.